Key Financial Data Of Group

Astellas Pharma Inc. - Filing #7303078

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
Key financial data of group
Business results of group
Revenue
935,621,000,000 JPY
1,603,672,000,000 JPY
767,138,000,000 JPY
Profit (loss) before tax
89,042,000,000 JPY
24,969,000,000 JPY
56,318,000,000 JPY
Profit (loss), attributable to owners of parent
73,511,000,000 JPY
17,045,000,000 JPY
35,810,000,000 JPY
Comprehensive income, attributable to owners of parent
1,393,000,000 JPY
205,583,000,000 JPY
192,674,000,000 JPY
Equity attributable to owners of parent
1,529,842,000,000 JPY
1,595,988,000,000 JPY
1,643,730,000,000 JPY
Total assets
3,462,237,000,000 JPY
3,569,603,000,000 JPY
3,547,406,000,000 JPY
Basic earnings (loss) per share
41.06
9.51
19.97
Diluted earnings (loss) per share
40.91
9.47
19.90
Ratio of owners' equity to gross assets
0.442 xbrli:pure
0.447 xbrli:pure
0.463 xbrli:pure
Cash flows from (used in) operating activities
77,411,000,000 JPY
172,475,000,000 JPY
53,222,000,000 JPY
Cash flows from (used in) investing activities
-55,732,000,000 JPY
-845,802,000,000 JPY
-787,454,000,000 JPY
Cash flows from (used in) financing activities
-66,259,000,000 JPY
614,060,000,000 JPY
670,156,000,000 JPY
Cash and cash equivalents
292,993,000,000 JPY
335,687,000,000 JPY
333,993,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.